MTNB Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice.
Quick AnswerMTNB — AI-powered stock analysis, price $0.1932, MoonshotScore 28/100.
Price as of Sep 11, 2026 · Last analyzed: Sep 10, 2026These figures come from statements filed 12 months ago — the most recent this company has published.
MTNB: 2/3 scored disciplines lean bearish. Dominant signal: Momentum weak.
How is this calculated? →Strongest side: Growth Durability (7/10, Moderate). Weakest side: Momentum (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MTNB Company Overview
Who Are MTNB's Competitors?
MTNB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $144.81 | -0.58% | $180B | 635-pillar |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are the Key Risks for MTNB?
Listing risk — at $0.1932 the shares sit below the $1.00 minimum bid AMEX requires for continued listing.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $2.5M recently.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 92% of our measures
- ● Price is current
- ● Latest filing 29 days ago
- ● No analyst coverage
Why 28?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.46 Price to book (Valuation)
- +0.19 Operating income growth (Growth)
- +0.17 Free cash flow growth (Growth)
What is holding it back
- -0.78 Return on assets (Business Quality)
- -0.78 Free cash flow yield (Business Quality)
- -0.60 Bankruptcy-risk score (Financial Strength)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 26 |
| 2026-08-26 | 26 |
| 2026-08-29 | 26 |
| 2026-09-01 | 27 |
| 2026-09-04 | 28 |
| 2026-09-07 | 28 |
| 2026-09-10 | 28 |
What changed?
The grade moved from 26 to 28 (+2).
What moved it up or down:
- +6 Valuation
- +2 Financial Safety
- +1 Business Quality
Over the same 18 days the stock moved -7.9%.
Insider Activity
Over the past six months, MTNB insiders filed 8 SEC Form 4 transactions — 3 sales and 5 purchases. On net that is roughly 3.1M shares disposed (about $2.5M), a signal worth weighing alongside the fundamentals.
Quarterly Financial Performance: MTNB
Revenue for MTNB came in at $0 during Q2 FY2026. The company recorded a net loss of $1.3M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in its sector. Across the four most recent quarters, MTNB averaged $-0.31 in diluted EPS.
MTNB Valuation & Market Position
Relative to its peer group, MTNB's quantitative score of 28/100 is below the peer average of 84/100.
Financial Health
MTNB's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
MTNB has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 43.5% above estimates on average.
Company Profile
MTNB operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bedminster, US. The company is led by CEO Jerome D. Jabbour. MTNB has traded publicly since 2014.
MTNB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$1M | -$0.21 |
| Q1 FY2026 | $0 | -$2M | -$0.30 |
| Q4 FY2025 | $0 | -$2M | -$0.35 |
| Q3 FY2025 | $0 | -$2M | -$0.40 |
Q2 FY2026 · filed 13 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
MTNB Latest News
-
Matinas Biopharma Obtains NYSE Noncompliance Notice
benzinga · Sep 4, 2026
-
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
globenewswire.com · Sep 4, 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Aug 20, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Aug 20, 2026
MTNB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MTNB.
Price Targets
Wall Street price target analysis for MTNB.
MTNB MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. MTNB scores 28/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
Matinas Biopharma Obtains NYSE Noncompliance Notice
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
MTNB Stock: Key Questions Answered
What does the AI Score mean for MTNB?
MTNB holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation.
Is MTNB a good stock?
Stock Expert AI does not rate MTNB buy, sell or hold. MTNB has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for MTNB?
Evaluate MTNB on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does MTNB data refresh on this page?
MTNB prices refresh on page view and on a rolling daily schedule; the last-updated date appears near the top of this page. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MTNB's recent stock price performance?
MTNB moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MTNB overvalued or undervalued right now?
MTNB has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of MTNB?
Yes, most major brokerages offer fractional shares of MTNB with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track MTNB's earnings and financial reports?
MTNB reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for MTNB earnings announcements.
What should investors new to MTNB understand first?
MTNB is worth researching across volatility, fundamentals, and industry context. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.